Related Experiment Videos
Vagus nerve stimulation for medically refractory epilepsy; efficacy and cost-benefit analysis
P Boon1, K Vonck, T Vandekerckhove
1Department of Neurology, Epilepsy Program University Hospital, Gent, Belgium.
Acta Neurochirurgica
|July 7, 1999
Summary
Vagus nerve stimulation (VNS) effectively reduces refractory epilepsy seizures and costs. This epilepsy treatment shows sustained efficacy over time, offering a cost-effective solution for patients unsuitable for surgery.
Area of Science:
- Neurology
- Neurosurgery
- Medical Economics
Background:
- Vagus nerve stimulation (VNS) is an emerging treatment for medically refractory epilepsy.
- It is indicated for patients ineligible for or with suboptimal outcomes from conventional epilepsy surgery.
- Existing studies have short follow-up periods, and cost-benefit analyses are limited.
Purpose of the Study:
- To evaluate the long-term efficacy of VNS in seizure control and severity.
- To conduct a cost-benefit analysis of VNS implantation.
- To assess epilepsy-related direct medical costs before and after VNS.
Main Methods:
- A cohort of 15 patients with refractory epilepsy, unsuitable for resective surgery, received VNS.
- Mean follow-up was 24 months (range: 7-43 months).
- Seizure frequency, severity, and epilepsy-related direct medical costs were compared pre- and post-implantation.
Main Results:
- A significant reduction in mean seizure frequency from 14 to 8 seizures/month (p=0.0016).
- Five patients achieved >50% seizure reduction; six became free of complex partial seizures.
- Epilepsy-related direct medical costs decreased significantly, from $8830/year to $4215/year (p=0.018), with a reduction in hospital days.
Conclusions:
- Vagus nerve stimulation is an effective and durable treatment for refractory epilepsy.
- Cost-benefit analysis indicates VNS costs are recouped within two years post-implantation.
- VNS offers a valuable therapeutic and economic option for select epilepsy patients.